Artificial Intelligence in Analyzing Patient Data for Precision Medicine

Md Shamsuddin Sultan Khan [1*], Md Mazedul Haq[2]

Abstract

Background: Precision medicine represents a transformative shift in disease diagnosis and patient care by integrating genetic, medical, and personal data. This approach surpasses traditional symptom-based methods by facilitating earlier interventions and tailored treatment plans. Methods: This review explores the role of artificial intelligence (AI) in precision medicine, focusing on its ability to analyze extensive patient datasets using advanced techniques such as deep learning and machine learning. These AI methods identify complex patterns and relationships within the data. Results: AI-driven analysis enables the creation of highly individualized treatment plans, enhancing the precision of medical interventions. The integration of AI in precision medicine leads to improved diagnostic accuracy and therapeutic efficacy. Conclusion: AI has the potential to revolutionize precision medicine by providing deeper insights into patient data, leading to more personalized and effective healthcare solutions. This advancement promises to enhance patient outcomes and transform the future of medical practice.

Significance | Integrating AI with precision medicine advances personalized healthcare by improving diagnostic accuracy and treatment efficacy, ultimately enhancing patient outcomes.

*Correspondence. Md Shamsuddin Sultan Khan, Neo7bioscience, Dallas, Texas, United States.
E-mail: jupitex@gmail.com

Editor Vishwanadham Mandala, Ph.D., And accepted by the Editorial Board March 14, 2020 (received for review January 20, 2020)

Keywords: Precision medicine, Artificial Intelligence, Treatment Efficacy, Medical Interventions.

1. Introduction

Artificial Intelligence (AI) is a rapidly evolving branch of computer science, with the goal of developing computers capable of performing tasks that typically require human intelligence. The scope of AI encompasses a variety of methodologies, including natural language processing (NLP), deep learning (DL), and machine learning (ML). Among the most promising innovations in the field of AI are Large Language Models (LLMs), which utilize deep learning methods and massive datasets to understand, summarize, generate, and predict text-based content (Suleimenov et al., 2020). These models are capable of performing a wide range of NLP tasks, including text generation, translation, summarization, rewriting, classification, categorization, and sentiment analysis. The central objective of LLMs is to generate coherent and meaningful text, closely mimicking human language. NLP, a subfield of AI, focuses on enabling machines to understand, interpret, and produce human language. Techniques used within NLP include sentiment analysis, speech recognition, text mining, and machine translation, all of which serve various purposes in AI-driven applications. The development of AI has undergone significant transformations since its inception, from early rule-based systems to the sophisticated machine learning and deep learning algorithms that are prevalent today (Davenport et al., 2016).

The history of AI dates back to the early 1950s, with the creation of the first AI program by Christopher Strachey in 1951. At this time, AI was still in its infancy, primarily confined to academic research. It was not until the Dartmouth Conference in 1956, where John

Author Affiliation.
[1] Neo7bioscience, Dallas, Texas, United States.
[2] Research Center of Bioactive Materials, Department of Bioactive Material Sciences, Division of Life Sciences Jeonbuk National University, South Korea.

Please Cite This:
Khan, M. S. S., Haq, M. M. (2020). "Artificial Intelligence in Analyzing Patient Data for Precision Medicine", Journal of Precision Biosciences, 2(1),1-11,2023

McCarthy coined the term "Artificial Intelligence," that AI as a formal discipline began to take shape. In the decades that followed, AI research focused on rule-based and expert systems, which aimed to model human decision-making. However, these early systems were limited by the available data and computational power (McCorduck et al., 2014). The 1980s and 1990s saw a shift toward machine learning (ML) and neural networks, which allowed computers to learn from data and improve over time. One notable achievement during this period was IBM's Deep Blue, which defeated world chess champion Garry Kasparov in 1997.

The 2000s brought further advancements, particularly in NLP and computer vision, resulting in virtual assistants such as Apple's Siri and Amazon's Alexa, which could understand and respond to spoken language (Figure 1) (Russell et al., 2010). These developments sparked significant interest in the broader application of AI across various sectors, including healthcare, banking, and transportation. In healthcare, AI has been used to develop intelligent tutoring systems that adapt to individual students' learning needs, resulting in improved educational outcomes in fields like science and mathematics.

In the context of healthcare, AI has demonstrated its capacity to analyze large datasets and identify patterns that might be difficult for humans to detect. This capability has led to breakthroughs in areas such as drug discovery and genomics. Furthermore, AI has been applied to healthcare settings to develop personalized treatment plans and diagnostic tools, enhancing the overall quality of patient care. As AI continues to advance, it is essential to ensure that its development remains ethical and aligned with the broader goal of improving public welfare (Jordan et al., 2015).

2. **Artificial Intelligence in Precision Medicine**

The rapid advancement of AI technologies offers substantial opportunities for their integration into clinical settings, with the potential to fundamentally transform healthcare delivery. A key focus of this review is to highlight the importance of recording and disseminating knowledge about the application of AI in healthcare to provide healthcare professionals with the resources they need to incorporate AI into patient care. By examining the current state of AI in healthcare, this article aims to explore the potential benefits, challenges, and future directions of the technology in clinical practice.

AI has already made significant contributions to the healthcare industry, with applications ranging from administrative tasks such as scheduling and billing to more complex functions like clinical decision support. Machine learning (ML), a subset of AI, has played an instrumental role in advancing personalized medicine. ML algorithms, which allow computers to learn from data and improve their performance over time, are particularly well-suited for processing large and complex datasets. The integration of AI into precision medicine relies on the use of these algorithms to assist in the identification of relevant patterns and associations within patient data, enabling the development of tailored treatment plans.

2.1 Machine Learning in Precision Medicine

Precision medicine is an emerging approach to healthcare that emphasizes individualized treatment based on genetic, environmental, and lifestyle factors. While precision medicine holds great promise, its success is largely dependent on the application of machine learning algorithms, which can process and analyze vast amounts of patient data to identify meaningful patterns. These algorithms allow healthcare providers to develop highly personalized treatment strategies that improve patient outcomes.

Common machine learning techniques used in precision medicine include support vector machines (SVM), deep learning, logistic regression, decision trees, random forests, linear regression, Naïve Bayes, k-nearest neighbors (KNN), and hidden Markov models (HMM). These techniques enable the analysis of clinical, genomic, metabolomic, imaging, claims, laboratory, nutritional, and lifestyle data, as illustrated in Figure 2 (not shown). By integrating multiple data sources, machine learning algorithms produce more accurate and reliable information than any individual dataset alone. This integrated approach allows for a more comprehensive understanding of patient health, which is essential for developing personalized treatment plans.

As AI continues to evolve, its application in healthcare will likely expand, leading to even more sophisticated and effective tools for disease diagnosis and treatment. The role of AI in precision medicine is poised to reshape the healthcare landscape, making it more data-driven and personalized than ever before.

However, the integration of artificial intelligence into healthcare, and particularly into precision medicine, represents a significant advancement in the ability to deliver individualized patient care. The continued development and application of machine learning and other AI technologies will undoubtedly transform healthcare delivery, providing more accurate diagnoses, personalized treatments, and improved patient outcomes. As AI continues to evolve, the challenge remains to ensure that its development and application are ethical, transparent, and aligned with the broader goal of enhancing public health.

3. **Advancements in AI for Effective Illness Diagnosis**

Despite significant progress in medical science, effective illness diagnosis remains a global challenge. The complexity of disease processes and overlapping symptoms often hinders early and accurate diagnosis. Artificial intelligence (AI), particularly machine learning (ML), offers transformative potential in addressing these challenges. Machine learning, a subset of AI, uses data as its primary resource. Its efficacy heavily depends on the quantity and quality of the input data, which aids in managing the complexities of diagnosis (Myszczynska et al., 2020). By assisting in decision-making, managing workflows, and automating tasks, ML ensures efficiency and cost-effectiveness. Deep learning techniques, such as Convolutional Neural Networks (CNNs), enhance ML by identifying intricate patterns within large datasets, making them indispensable tools for disease detection (Ahsan et al., 2022).

3.1 AI in Cancer Diagnosis

AI's application in cancer diagnosis demonstrates its transformative capabilities. A UK study published in Scientific Reports trained an AI system on a large mammogram dataset to detect breast cancer. The system achieved significant reductions in false positives and false negatives by 5.7% and 9.4%, respectively (McKinney et al., 2022). Similarly, a South Korean study revealed AI's superior sensitivity in breast cancer diagnosis, achieving a 90% rate compared to radiologists' 78% for mass-based diagnoses. AI also identified early breast cancer with a 91% sensitivity rate, outperforming radiologists' 74% (Kim et al., 2020).

Deep learning has also proven effective in dermatology. For example, a CNN-based AI system demonstrated comparable accuracy to dermatologists in diagnosing melanoma, highlighting its potential in skin cancer detection (Han et al., 2020). AI technologies have also been employed for diabetic retinopathy diagnosis (Haenssle et al., 2018), electrocardiogram abnormalities, and cardiovascular disease risk prediction (Alfaras et al., 2019). For pneumonia diagnosis, deep learning algorithms achieved 96% sensitivity and 64% specificity, surpassing radiologists' respective rates of 50% and 73% (Becker et al., 2022).

3.2 AI in Early Disease Detection

AI also shows promise in diagnosing acute conditions. For instance, a study involving 625 cases utilized various ML techniques to predict acute appendicitis and the need for surgery. The random forest algorithm emerged as the most accurate, achieving an 83.75% prediction rate with 84.11% precision, 81.08% sensitivity, and 81.01% specificity. Such methods not only enhance appendicitis diagnosis but also offer the potential for broader applications, such as analyzing COVID-19 cases using blood samples or images (Mijwil et al., 2022).

3.3 AI in Clinical Laboratory Testing

Clinical laboratory testing is critical for diagnosing, treating, and monitoring diseases. AI is revolutionizing this domain by improving accuracy, speed, and efficiency. Machine learning algorithms have been developed for microbial identification, classification, and antibiotic susceptibility testing. These models utilize data from various sources, including gene sequencing, metagenomic results, microbial genomic data, and microscopic imaging (Peiffer-Smadja et al., 2020).

AI-driven techniques also play a pivotal role in gram staining, with deep convolutional neural networks achieving high sensitivity and specificity in distinguishing gram-positive and gram-negative bacteria, as well as cocci and rods (Smith et al., 2018). A systematic review highlighted the utility of ML models for microbial identification and susceptibility testing, although further refinement is necessary before clinical implementation (Weis et al., 2020).

In malaria diagnosis, digital in-line holographic microscopy (DIHM) combined with ML enables rapid and stain-free detection of infected red blood cells. This AI system is not only accurate but also cost-effective, making it ideal for resource-limited settings (Go et al., 2018).

3.4 Automation in Clinical Microbiology

Automation and AI integration in clinical microbiology labs have significantly improved productivity. Automated systems for susceptibility testing, blood cultures, and molecular platforms enable faster and more accurate results. For example, automated systems can deliver actionable results within 24 to 48 hours for patients with positive blood cultures, facilitating timely selection of appropriate antibiotic treatments (Vandenberg et al., 2020). This approach is critical for achieving high cure rates for infectious diseases.

3.5 AI-Powered Decision Support Systems

AI-powered decision support systems (DSS) offer real-time recommendations for diagnosis and treatment. These systems are particularly valuable in emergency departments (EDs), where rapid clinical data interpretation is crucial for prioritizing care. Limited patient information often forces clinicians to rely on probabilities, increasing the risk of diagnostic errors. Diagnostic mistakes are closely linked to higher mortality rates and extended hospital stays, particularly in ED settings (Hautz et al., 2019).

AI addresses these challenges by identifying early-stage life-threatening conditions and promptly alerting healthcare providers. Moreover, AI optimizes resource utilization by predicting patient demand, selecting appropriate therapies (drug, dosage, and mode of administration), and recommending ED stay durations. By analyzing patient-specific data, AI systems enhance efficiency and reduce overcrowding, ultimately improving patient outcomes.

3.6 The Path Forward for AI in Diagnostics

Although AI has demonstrated its potential across various diagnostic applications, there are still challenges to overcome. Ensuring the ethical use of AI, maintaining data privacy, and addressing biases in algorithms are critical for successful implementation. Additionally, integrating AI into clinical workflows requires collaboration between technologists, clinicians, and policymakers.

AI's growing role in diagnostics also highlights the importance of training healthcare professionals to understand and leverage these technologies. By fostering interdisciplinary collaboration and education, the healthcare industry can maximize AI's potential to improve patient care.

AI is poised to transform healthcare by enhancing diagnostic accuracy, efficiency, and accessibility. From cancer and skin disease detection to clinical laboratory testing and decision support systems, AI is revolutionizing the way diseases are diagnosed and treated. However, achieving its full potential requires addressing challenges such as ethical considerations, data privacy, and integration into existing systems. As AI technology continues to evolve, its role in healthcare will undoubtedly expand, offering new opportunities to improve patient outcomes worldwide.

4. AI in genomic medicine

The integration of artificial intelligence (AI) with genetic analysis holds tremendous potential for advancing disease surveillance, prediction, and personalized therapy (Haug et al., 2023). AI can monitor emerging health threats, such as COVID-19, across large populations by analyzing real-time data. Moreover, genomic data offers critical insights into genetic markers that correlate with increased susceptibility to specific diseases (Abubaker et al., 2022). By training machine learning (ML) algorithms to recognize these markers, early identification of potential epidemics becomes achievable, enabling timely public health interventions (Figure 3).

Genomic data also improves disease risk prediction by uncovering intricate patterns of genetic variation. ML algorithms excel at identifying these patterns, often missed by traditional statistical methods, which enhances the accuracy of genotype-based risk projections. Additionally, AI facilitates the prediction of phenotypes—observable traits shaped by genetic and environmental factors. These phenotypes range from simple characteristics, like eye color, to complex traits, such as drug response or disease susceptibility.

A notable example of AI's efficacy is its ability to detect genetic variations linked to specific traits or diseases. Through the analysis of extensive genomic datasets, AI identifies complex patterns that are challenging to discern manually. For instance, a deep neural network was used in a groundbreaking study to predict the presence of autism spectrum disorder (ASD) solely based on genomic data, identifying key genetic variations associated with ASD (Wang et al., 2021).

4.1 AI in Oncology and Tumor Classification

In oncology, transcriptome profiling—analyzing gene expression data—has proven invaluable for categorizing tumors into clinically relevant molecular subgroups. These categories, initially developed for breast cancer, now extend to ovarian, colorectal, and sarcoma cancers, significantly influencing diagnosis, prognosis, and therapy selection (Yersal et al., 2014).

Traditional computational methods, such as support vector machines (SVMs) and k-nearest neighbors, have been used for tumor subtyping. However, these methods are prone to errors from batch effects and often focus on a limited set of signature genes, neglecting critical biological information (Scharpf et al., 2010). The advent of AI and ML, coupled with high-throughput genomic sequencing technologies, has addressed these limitations, creating robust frameworks for accurate cancer classification.

4.2 AI in Personalized Medicine and Drug Discovery

AI has profoundly impacted personalized medicine and drug discovery. The complexity of large-scale genomic data presents challenges for interpretation, but AI and ML provide tools to analyze such data effectively. These tools facilitate the identification of novel therapeutic targets and the repurposing of existing drugs for new indications by simultaneously analyzing genetic information and clinical data, including drug efficacy and side effects (Tran et al., 2023).

One critical area where AI contributes significantly is predicting drug toxicity. Non-clinical toxicity remains a major barrier in drug development, leading to high failure rates in clinical trials. Computer modeling, powered by AI, enables the prediction of drug toxicity, particularly in common categories such as cardiotoxicity and hepatotoxicity. This predictive capability is crucial for improving the drug development process and preventing post-market drug withdrawals (Guedj et al., 2022).

AI's integration with genomics is revolutionizing medicine by enabling more precise disease prediction, effective surveillance, and personalized treatment strategies. From identifying genetic markers of disease susceptibility to improving drug development, AI offers powerful tools to unlock the full potential of genomic data. By addressing challenges such as toxicity prediction and refining traditional analytical methods, AI is poised to drive innovation in genomic medicine, ultimately improving healthcare outcomes globally.

5. AI assistance in treatment

5.1 Precision medicine and clinical decision support

5.1 Precision medicine and clinical decision support

Personalized therapy, sometimes referred to as precision medicine or personalized medicine, is a therapeutic method that customizes medical care for individual patients according to their distinct attributes, including genetics, lifestyle, environment, and biomarkers (Ahmed et al,2023). With more focused, safe, and efficient therapies, this customized strategy seeks to enhance patient outcomes.

With its ability to evaluate large, complicated information, forecast results, and improve treatment plans, artificial intelligence (AI) has shown itself to be a useful instrument in the advancement of personalized medicine (Subramanian et al,2020). One innovative area that shows the promise of precision medicine on a broad scale is personalized therapy (Johnson et al,2021). However, real-time



Figure 1. Evolution of Artificial Intelligence (AI) and Its Interconnections with Machine Learning (ML), Deep Learning (DL), and Natural Language Processing (NLP).



Figure 2. The Role of Machine Learning (ML) Algorithms in Healthcare. This diverse applications of machine learning (ML) algorithms in healthcare, including disease detection, personalized treatment planning, predictive analytics, and patient management.



Figure 3. Genomic Data Analysis for Disease Prediction. This figure outlines the process beginning with the extraction of DNA/RNA, followed by sequencing to obtain genetic information. The sequenced data is then aligned at the genotypic level using neural networks and deep learning techniques. Statistical methods are applied to calculate the probability of specific diseases (such as hypertension, depression, breast cancer, and Alzheimer's disease) based on genetic mutations. The Y-axis represents the probability (in percentage) of disease occurrence, while the X-axis shows the number of gene mutations. Negative values on the X-axis indicate gene deletions, while positive values correspond to gene additions or nucleic acid mutations. This process highlights the integration of advanced computational techniques in predicting disease risk based on genomic data.



Figure 4. Unlocking the Power of Patient Data Through AI-Driven Predictive Analytics. AI-driven predictive analytics harnesses patient data to forecast health outcomes. By analyzing various data points, including medical history, demographics, and lifestyle factors, AI algorithms identify patterns and predict the likelihood of future events, such as hospital readmissions or the development of chronic diseases. The integration of these predictive models into clinical decision-making helps optimize healthcare interventions, improve patient care, and reduce costs.

suggestion capabilities depend on the development of machine learning algorithms that can anticipate patients who might need particular drugs based on their genetic makeup. Preemptive genotyping of patients before the real need for such information arises is the key to customizing drugs and doses for individual individuals (Pulley et al,2012).

AI has garnered respect for its ability to help doctors make treatment decisions, especially when it comes to predicting therapeutic response (Pulley et al,2012). Huang et al.'s work, in which the authors trained a support machine learning model using the gene expression data of the patients, correctly predicted the treatment response (Huang et al,2018). The authors of this study used the gene-expression profiles of 175 cancer patients to predict how the patients will react to different standard-of-care chemotherapy treatments. Notably, the study had positive results, with over 80% prediction accuracy across a range of medications. These results show how promising AI is for predicting therapy response.

In another work done by Sheu et al., the authors aimed to predict the response to different classes of antidepressants using electronic health records (EHR) of 17,556 patients using AI (Shue et al,2023). In order to reduce confounding variables, the AI models took into account qualities that were predictive of treatment selection, and they performed well in predictions.The study showed that real-world EHR data may be used to properly predict antidepressant response using AI modeling, indicating the possibility for creating clinical decision support systems to aid in the choosing of treatments more successfully. Although a great deal of progress has been achieved in using AI and genomics to predict treatment results, more prospective and retrospective clinical research and investigations must be carried out (Shue et al,2023). . These initiatives are essential for producing the thorough data needed to efficiently train the algorithms, guarantee their dependability in practical situations, and advance the development of AI-based clinical decision support systems.

6. Dosage Optimization and Adverse Drug Event Prediction

Artificial intelligence (AI) significantly enhances dosage optimization and predicts adverse medication events, ultimately improving patient safety and treatment outcomes (Martin et al., 2020). By leveraging AI algorithms, healthcare professionals can anticipate potential drug-related risks and tailor medication doses to individual patients, reducing harm and optimizing therapeutic efficacy.

A notable example is the development of a decision support system for optimizing warfarin maintenance dosage and predicting prothrombin time international normalized ratio (PT/INR) values using AI (Lee et al., 2021). Researchers analyzed data from 19,719 inpatients across three institutions, demonstrating that their AI algorithm outperformed experienced clinicians in predicting future PT/INR levels. The algorithm reliably generated personalized warfarin dosages, highlighting its potential for improving anticoagulation therapy.

Another innovative AI-driven system is CURATE.AI, which dynamically optimizes chemotherapy doses based on patient-specific data (Blasiak et al., 2022). In an open-label, prospective trial involving patients receiving three distinct chemotherapy regimens for advanced solid tumors, CURATE.AI personalized subsequent doses by analyzing the relationship between tumor marker responses and chemotherapy dose variations. Compared to standard care, the system demonstrated the potential to reduce chemotherapy dosages while improving patient response rates and durations. These findings underscore AI's capacity to refine chemotherapy dosing and reduce adverse drug events, though further validation through randomized clinical trials is essential.

Therapeutic drug monitoring (TDM) aims to optimize medication dosages for individual patients, particularly for drugs with narrow therapeutic indices. TDM minimizes the risk of adverse effects and ensures that patients receive the correct medication at the right dose and time to achieve therapeutic goals (Partin et al., 2023). AI has the potential to revolutionize TDM by predicting individual responses to medications based on genetic profiles, medical histories, and other factors, enabling more precise and effective treatment strategies (Zhang et al., 2021).

One application of AI in TDM involves machine learning (ML) algorithms that predict drug-drug interactions. By analyzing large patient datasets, these algorithms can identify potential interactions that may lead to adverse drug events, ultimately improving safety, reducing costs, and enhancing outcomes (Han et al., 2022). Predictive analytics is another powerful AI application in TDM, helping to identify patients at higher risk of negative drug interactions. By evaluating patient data and detecting risk factors, healthcare providers can take proactive measures to prevent unfavorable outcomes (Lui et al., 2023).

AI is transforming dosage optimization and adverse drug event prediction. By integrating AI into clinical workflows, healthcare professionals can deliver safer, more effective, and personalized care, advancing patient safety and treatment efficacy. Continued research and validation are essential to fully realize AI's potential in therapeutic drug monitoring and beyond.

7. AI assistance in population health management

7.1 Predictive analytics and risk assessment

Predictive analytics is increasingly being employed in population health management to identify and guide health interventions (Figure 4). As a branch of data analytics, predictive analytics leverages artificial intelligence (AI), machine learning (ML), data mining, and modeling to analyze historical and real-time data to forecast future trends (Amarasingham et al., 2014). By applying ML algorithms and advanced technologies, predictive models are developed to enhance patient outcomes and reduce healthcare costs.

One application of predictive analytics is the identification of individuals at risk for chronic illnesses, such as cardiovascular or endocrine disorders. By evaluating factors such as medical history, demographics, and lifestyle, predictive models can pinpoint individuals with a higher likelihood of developing these conditions and guide interventions to prevent or treat them (Nelson et al., 2021).

Another significant use of predictive analytics is in predicting hospital readmissions. Predictive models analyze patient data to identify those at higher risk of readmission, enabling targeted interventions to prevent such occurrences (Fig. 4) (Donze et al., 2013). This proactive approach can reduce healthcare costs and improve patient outcomes. For instance, new initiatives like "Reveal®" have emerged to capitalize on the potential of predictive analytics in reducing readmissions (PHA, 2023).

AI plays a pivotal role in enhancing the accuracy and efficiency of predictive models. By analyzing vast datasets and uncovering patterns that may escape human analysts, AI algorithms improve the precision of predictions and ensure optimal patient care. Additionally, AI can automate various public health management tasks, such as care coordination and patient outreach, ensuring timely and appropriate interventions while reducing costs (Nelson et al., 2021).

However, the success of predictive analytics in public health management heavily depends on the quality of the underlying data and the robustness of the technological infrastructure. High-quality data is essential to create accurate models, and human oversight remains critical to ensure the appropriateness and effectiveness of interventions for at-risk patients.

From a Saudi perspective, predictive analytics has shown potential for addressing the nation's top health concerns, including diabetes, cancer, heart disease, and skin conditions. For example, the big data analytics tool Sehaa in Saudi Arabia utilizes Twitter data to diagnose diseases (Crossnohere et al., 2022). Of the fourteen diseases identified, Riyadh exhibited the highest awareness-to-afflicted ratio for six conditions, while Taif emerged as the healthiest city with the fewest cases and the most awareness campaigns. These insights highlight the need for targeted interventions to prevent and manage chronic illnesses in Saudi Arabia, underscoring the value of predictive analytics in population health management.

Predictive analytics, supported by AI and advanced technologies, has the potential to transform population health management. By enabling accurate predictions and automating critical tasks, it improves healthcare precision and efficiency. However, its successful implementation depends on high-quality data, sophisticated infrastructure, and continuous human oversight to ensure effective and ethical interventions (Amarasingham et al., 2014).

8. Limitations of AI in advancing personalized medicine

The application of artificial intelligence (AI) in creating personalized medications faces several limitations. Below, we explore some of the most critical challenges.

8.1 Overreliance on Population-Level Data

AI-driven big data analysis often prioritizes patterns derived from population-level correlations, potentially overlooking significant individual-level insights (Fisher et al., 2018). Many models lack "ergodicity," meaning they are not necessarily useful for tailoring individual therapies. Ideally, as more data points are collected from an individual, predictions for their health trajectory should prioritize their personal data over population-level trends. This approach can account for changes in the individual's health status that may not align with broader patterns observed across larger datasets (Drescher et al., 2013). Progress in personalized medicine demands AI methodologies that emphasize individual-level dynamics.

8.2 Evaluating AI-Based Healthcare Products

The effectiveness of AI-based healthcare products requires rigorous evaluation. Uneven outcomes, such as those observed with IBM Watson's treatment decision support system, underscore the need for robust testing protocols (Zhou et al., 2018). While some AI-driven tools have demonstrated efficacy in randomized clinical trials, the reliability of others remains questionable, particularly if trained on biased or inadequate datasets. Google's flu epidemic prediction system serves as a cautionary example of how biases in training data can compromise predictions (Lazer et al., 2014).

Concerns also arise in the context of basket trials when AI systems are used to match medications to patient profiles. If the underlying matching algorithm is flawed or fails to outperform standard-of-care practices, the system's overall efficacy may be significantly compromised. For instance, medications might work inconsistently or fail entirely, not because of inherent inefficacy but due to poor matching of drugs to patient profiles (Le et al., 2015).

8.3 Iterative Learning and Validation

AI-based decision support tools often employ learning systems where algorithms are continuously updated. While this iterative approach may improve long-term accuracy, it requires unbiased initial datasets and substantial time for the system to mature and provide reliable results (Ioannidis et al., 2018). A reliance on biased data during early development stages can undermine the generalizability and trustworthiness of findings.

8.4 The "Black Box" Problem

Many AI-based decision support systems rely on deep learning and neural networks, which, although capable of highly accurate predictions with large datasets, often lack interpretability. This "black box" issue can lead to mistrust, especially in high-stakes clinical settings where lives are at risk (Voosen et al., 2017).

Moreover, most AI methods focus on correlations rather than causation. While correlations may suffice for making accurate predictions, causal relationships are critical for identifying drug targets that produce specific therapeutic effects when altered (Marwala et al., 2015). Without understanding causation, the development of effective, targeted interventions becomes challenging, limiting the broader application of AI in personalized medicine.

AI holds great promise in advancing personalized medicine, but several limitations must be addressed to maximize its potential. Ensuring models are designed to incorporate individual-level data, rigorously evaluating AI-based tools, adopting iterative learning systems, and overcoming the "black box" issue are critical steps. By addressing these challenges, AI can more effectively contribute to developing customized medications and improving patient outcomes.

9. Conclusion

Artificial intelligence (AI) has immense potential to revolutionize healthcare, transforming patient care and outcomes through improved accuracy, efficiency, and cost-effectiveness. AI-driven predictive analytics can enhance clinical laboratory testing, disease detection, and population health management by optimizing pharmaceutical decisions and providing real-time insights. Moreover, AI's application in virtual health and mental health assistance demonstrates promise in improving patient care. However, for these advancements to be ethical and equitable, addressing challenges such as bias, lack of customization, and data privacy is paramount.

To ensure the successful and ethical integration of AI in healthcare, several critical measures are needed. Comprehensive cybersecurity frameworks and robust data protection strategies must be implemented to safeguard sensitive patient information and healthcare operations. Establishing clear regulations and standards in collaboration with healthcare organizations, AI researchers, and regulatory bodies is essential for the responsible use of AI in clinical decision-making. Additionally, significant investment in research and development is required to design AI solutions tailored to the unique challenges of healthcare.

AI's ability to analyze variables such as geographic distribution, disease prevalence, and population demographics offers new opportunities for precision medicine. By identifying patients at risk of developing specific conditions, AI can support proactive treatment and prevention strategies. Furthermore, tools like edge analytics can detect trends and predict future medical needs, ensuring the timely availability of resources such as vaccines.

Public perception of AI in healthcare remains mixed, with many individuals willing to embrace AI for certain tasks while still preferring human doctors for complex issues. Building trust, educating patients, and addressing concerns about bias, privacy, and the role of human expertise are crucial for the widespread acceptance and successful application of AI.

Collaboration among stakeholders—including patients, providers, researchers, and policymakers—is vital to creating ethical AI systems and fostering trust. Multidisciplinary efforts and continued innovation are necessary to overcome existing barriers and unlock AI's full potential in healthcare. With thoughtful integration, AI is poised to transform healthcare by improving patient outcomes, enhancing operational efficiency, and expanding access to personalized, high-quality care.

Author contributions

M.S.S.K. conceptualized the study, designed the methodology, and supervised the overall research process. M.M.H. conducted the data analysis, prepared the visualizations, and contributed to the interpretation of results. Both authors were involved in drafting the manuscript, revising it critically for important intellectual content, and approved the final version of the manuscript for submission.

Acknowledgment

The authors were grateful to their department.

Competing financial interests

The authors have no conflict of interest.

References

Abràmoff, M. D., Lavin, P. T., Birch, M., Shah, N., & Folk, J. C. (2018). Pivotal trial of an autonomous AI-based diagnostic system for detection of diabetic retinopathy in primary care offices. NPJ digital medicine, 1(1), 39.

Ahmed, F., Kang, I. S., Kim, K. H., Asif, A., Rahim, C. S. A., Samantasinghar, A., ... & Choi, K. H. (2023). Drug repurposing for viral cancers: A paradigm of machine learning, deep learning, and virtual screening-based approaches. Journal of Medical Virology, 95(4), e28693.

Alfaras, M., Soriano, M. C., & Ortín, S. (2019). A fast machine learning model for ECG-based heartbeat classification and arrhythmia detection. Frontiers in Physics, 103.

Alowais, S. A., Alghamdi, S. S., Alsuhebany, N., Alqahtani, T., Alshaya, A. I., Almohareb, S. N., ... & Albekairy, A. M. (2023). Revolutionizing healthcare: the role of artificial intelligence in clinical practice. BMC medical education, 23(1), 689.

Amarasingham, R., Patzer, R. E., Huesch, M., Nguyen, N. Q., & Xie, B. (2014). Implementing electronic health care predictive analytics: considerations and challenges. Health affairs, 33(7), 1148-1154.

Becker, J., Decker, J. A., Römmele, C., Kahn, M., Messmann, H., Wehler, M., ... & Scheurig-Muenkler, C. (2022). Artificial intelligence-based detection of pneumonia in chest radiographs. Diagnostics, 12(6), 1465.

Berlyand, Y., Raja, A. S., Dorner, S. C., Prabhakar, A. M., Sonis, J. D., Gottumukkala, R. V., ... & Yun, B. J. (2018). How artificial intelligence could transform emergency department operations. The American journal of emergency medicine, 36(8), 1515-1517.

Blanco-Gonzalez, A., Cabezon, A., Seco-Gonzalez, A., Conde-Torres, D., Antelo-Riveiro, P., Pineiro, A., & Garcia-Fandino, R. (2023). The role of ai in drug discovery: challenges, opportunities, and strategies. Pharmaceuticals, 16(6), 891.

Blanco-Gonzalez, A., Cabezon, A., Seco-Gonzalez, A., Conde-Torres, D., Antelo-Riveiro, P., Pineiro, A., & Garcia-Fandino, R. (2023). The role of ai in drug discovery: challenges, opportunities, and strategies. Pharmaceuticals, 16(6), 891.

Crossnohere, N. L., Elsaid, M., Paskett, J., Bose-Brill, S., & Bridges, J. F. (2022). Guidelines for artificial intelligence in medicine: literature review and content analysis of frameworks. Journal of Medical Internet Research, 24(8), e36823.

Donzé, J., Aujesky, D., Williams, D., & Schnipper, J. L. (2013). Potentially avoidable 30-day hospital readmissions in medical patients: derivation and validation of a prediction model. JAMA internal medicine, 173(8), 632-638.

Drescher, C. W., Shah, C., Thorpe, J., O'Briant, K., Anderson, G. L., Berg, C. D., ... & McIntosh, M. W. (2013). Longitudinal screening algorithm that incorporates change over time in CA125 levels identifies ovarian cancer earlier than a single-threshold rule. Journal of clinical oncology, 31(3), 387.

Esteva, A., Kuprel, B., Novoa, R. A., Ko, J., Swetter, S. M., Blau, H. M., & Thrun, S. (2017). Dermatologist-level classification of skin cancer with deep neural networks. nature, 542(7639), 115-118.

Fisher, A. J., Medaglia, J. D., & Jeronimus, B. F. (2018). Lack of group-to-individual generalizability is a threat to human subjects research. Proceedings of the National Academy of Sciences, 115(27), E6106-E6115

Gandhi, S. O., Gandhi, S., & Sabik, L. (2014). Emergency department visit classification using the NYU algorithm.

Gellman, L. (2015). THE WALL STRETJ0URNAL.

Guedj, M., Swindle, J., Hamon, A., Hubert, S., Desvaux, E., Laplume, J., ... & Moingeon, P. (2022). Industrializing AI-powered drug discovery: lessons learned from the Patrimony computing platform. Expert Opinion on Drug Discovery, 17(8), 815-824.

Haenssle, H. A., Fink, C., Schneiderbauer, R., Toberer, F., Buhl, T., Blum, A., ... & Zalaudek, I. (2018). Man against machine: diagnostic performance of a deep learning convolutional neural network for dermoscopic melanoma recognition in comparison to 58 dermatologists. Annals of oncology, 29(8), 1836-1842.

Han, K., Cao, P., Wang, Y., Xie, F., Ma, J., Yu, M., ... & Wan, J. (2022). A review of approaches for predicting drug–drug interactions based on machine learning. Frontiers in pharmacology, 12, 814858.

Han, S. S., Park, I., Chang, S. E., Lim, W., Kim, M. S., Park, G. H., ... & Na, J. I. (2020). Augmented intelligence dermatology: deep neural networks empower medical professionals in diagnosing skin cancer and predicting treatment options for 134 skin disorders. Journal of Investigative Dermatology, 140(9), 1753-1761.

Haug, C. J., & Drazen, J. M. (2023). Artificial intelligence and machine learning in clinical medicine, 2023. New England Journal of Medicine, 388(13), 1201-1208.

Hautz, W. E., Kämmer, J. E., Hautz, S. C., Sauter, T. C., Zwaan, L., Exadaktylos, A. K., ... & Schauber, S. K. (2019). Diagnostic error increases mortality and length of hospital stay in patients presenting through the emergency room. Scandinavian journal of trauma, resuscitation and emergency medicine, 27(1), 1-12.

Huang, C., Clayton, E. A., Matyunina, L. V., McDonald, L. D., Benigno, B. B., Vannberg, F., & McDonald, J. F. (2018). Machine learning predicts individual cancer patient responses to therapeutic drugs with high accuracy. Scientific reports, 8(1), 16444.

Ioannidis, J. P., & Khoury, M. J. (2018). Evidence-based medicine and big genomic data. Human molecular genetics, 27(R1), R2-R7.

Kazancigil, M. A. (2022). Big medical data, cloud computing, and artificial intelligence for improving diagnosis in healthcare. In Big Data Analytics for Healthcare (pp. 139-150). Academic Press.

Kim, H. E., Kim, H. H., Han, B. K., Kim, K. H., Han, K., Nam, H., ... & Kim, E. K. (2020). Changes in cancer detection and false-positive recall in mammography using artificial intelligence: a retrospective, multireader study. The Lancet Digital Health, 2(3), e138-e148.

Lazer, D., Kennedy, R., King, G., & Vespignani, A. (2014). The parable of Google Flu: traps in big data analysis. science, 343(6176), 1203-1205.

Le Tourneau, C., Delord, J. P., Gonçalves, A., Gavoille, C., Dubot, C., Isambert, N., ... & Paoletti, X. (2015). Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. The lancet oncology, 16(13), 1324-1334.

Leek, J. T., Scharpf, R. B., Bravo, H. C., Simcha, D., Langmead, B., Johnson, W. E., ... & Irizarry, R. A. (2010). Tackling the widespread and critical impact of batch effects in high-throughput data. Nature Reviews Genetics, 11(10), 733-739.

Li, S., Zhao, R., & Zou, H. (2022). Artificial intelligence for diabetic retinopathy. Chinese Medical Journal, 135(03), 253-260.

Martin, G. L., Jouganous, J., Savidan, R., Bellec, A., Goehrs, C., Benkebil, M., ... & French Network of Pharmacovigilance Centres. (2022). Validation of artificial intelligence to support the automatic coding of patient adverse drug reaction reports, using nationwide pharmacovigilance data. Drug Safety, 45(5), 535-548.

Marwala, T. (2015). Causality, correlation and artificial intelligence for rational decision making. World Scientific.

McCorduck, P., & Cfe, C. (2004). Machines who think: A personal inquiry into the history and prospects of artificial intelligence. CRC Press.

McKinney, S. M., Sieniek, M., Godbole, V., Godwin, J., Antropova, N., Ashrafian, H., ... & Shetty, S. (2020). International evaluation of an AI system for breast cancer screening. Nature, 577(7788), 89-94.

Myszczynska, M. A., Ojamies, P. N., Lacoste, A. M., Neil, D., Saffari, A., Mead, R., ... & Ferraiuolo, L. (2020). Applications of machine learning to diagnosis and treatment of neurodegenerative diseases. Nature Reviews Neurology, 16(8), 440-456.

Nelson, K. M., Chang, E. T., Zulman, D. M., Rubenstein, L. V., Kirkland, F. D., & Fihn, S. D. (2019). Using predictive analytics to guide patient care and research in a national health system. Journal of general internal medicine, 34, 1379-1380.

Peiffer-Smadja, N., Dellière, S., Rodriguez, C., Birgand, G., Lescure, F. X., Fourati, S., & Ruppé, E. (2020). Machine learning in the clinical microbiology laboratory: has the time come for routine practice?. Clinical Microbiology and Infection, 26(10), 1300-1309.

Pudjihartono, N., Fadason, T., Kempa-Liehr, A. W., & O'Sullivan, J. M. (2022). A review of feature selection methods for machine learning-based disease risk prediction. Frontiers in Bioinformatics, 2, 927312.

Quazi, S. (2022). Artificial intelligence and machine learning in precision and genomic medicine. Medical Oncology, 39(8), 120.

Raghunath, S., Pfeifer, J. M., Ulloa-Cerna, A. E., Nemani, A., Carbonati, T., Jing, L., ... & Haggerty, C. M. (2021). Deep neural networks can predict new-onset atrial fibrillation from the 12-lead ECG and help identify those at risk of atrial fibrillation–related stroke. Circulation, 143(13), 1287-1298.

Russell, S. J., & Norvig, P. (2010). Artificial intelligence a modern approach. London.

Schmidt, C. (2017). MD Anderson breaks with IBM Watson, raising questions about artificial intelligence in oncology.

Singh, D. P., & Kaushik, B. (2023). A systematic literature review for the prediction of anticancer drug response using various machine-learning and deep-learning techniques. Chemical Biology & Drug Design, 101(1), 175-194.

Topol, E. J. (2019). High-performance medicine: the convergence of human and artificial intelligence. Nature medicine, 25(1), 44-56.

Tran, T. T. V., Surya Wibowo, A., Tayara, H., & Chong, K. T. (2023). Artificial Intelligence in Drug Toxicity Prediction: Recent Advances, Challenges, and Future Perspectives. Journal of Chemical Information and Modeling, 63(9), 2628-2643.

Undru, T. R., Utkarsha, U. D. A. Y., Lakshmi, J. T., Kaliappan, A., Mallamgunta, S., Nikhat, S. S., ... & Archana, G. A. U. R. (2022). Integrating Artificial Intelligence for Clinical and Laboratory Diagnosis–a Review. Maedica, 17(2), 420.

Voosen, P. (2017). The AI detectives Science, 357(6346): p. 22–27.

Weis, C. V., Jutzeler, C. R., & Borgwardt, K. (2020). Machine learning for microbial identification and antimicrobial susceptibility testing on MALDI-TOF mass spectra: a systematic review. Clinical Microbiology and Infection, 26(10), 1310-1317.

Zhang, H., Chen, Y., & Li, F. (2021). Predicting anticancer drug response with deep learning constrained by signaling pathways. Frontiers in Bioinformatics, 1, 639349.

Zhou, N., Zhang, C. T., Lv, H. Y., Hao, C. X., Li, T. J., Zhu, J. J., ... & Zhang, X. C. (2019). Concordance study between IBM Watson for oncology and clinical practice for patients with cancer in China. The oncologist, 24(6), 812-819.